Shopping Cart
- Remove All
- Your shopping cart is currently empty
TDO-IN-1 is an orally active, potent, and selective inhibitor of tryptophan 2,3-dioxygenase (TDO), inhibiting indoleamine-2,3-dioxygenase, with antitumor activity that reverses local immune tolerance in tumor tissues.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $117 | In Stock | |
2 mg | $169 | In Stock | |
5 mg | $289 | In Stock | |
10 mg | $455 | In Stock | |
25 mg | $892 | In Stock | |
50 mg | $1,450 | In Stock | |
100 mg | $1,970 | In Stock |
Description | TDO-IN-1 is an orally active, potent, and selective inhibitor of tryptophan 2,3-dioxygenase (TDO), inhibiting indoleamine-2,3-dioxygenase, with antitumor activity that reverses local immune tolerance in tumor tissues. |
Targets&IC50 | MOLM-13:3.43 μM, HepG2 cells:0.54 μM, H22:1.34 μM, TDO:0.62 μM, B16:37.39 μM, Jurkat cells:7.25 μM, Hepa1-6:5.08 μM |
In vitro | TDO-IN-1 (HT-28) exhibits significant tumoricidal effects on various tumor lines at concentrations ranging from 0 to 100 μM over 24 hours, with IC50 values of 0.54 μM (HepG2), 5.08 μM (Hepa1-6), 1.34 μM (H22), 37.39 μM (B16), 3.43 μM (MOLM-13), and 7.25 μM (Jurkat)[1]. Additionally, TDO-IN-1 (0-100 μM; 24 h) shows minimal cytotoxicity against normal cells (HEK 293) at concentrations below 10 μM[1]. |
In vivo | Administered orally at a dose of 25 mg/kg once daily for 9 days, TDO-IN-1 (HT-28) enhances the efficacy of tumor immunotherapy in CT26 tumors expressing TDO. This treatment substantially inhibits the proliferation of CT26 tumors in mice[1]. |
Molecular Weight | 350.3 |
Formula | C16H13F3N4O2 |
Cas No. | 2490672-92-7 |
Storage | store at low temperature | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 60 mg/mL (171.28 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.